“Lebrikizumab Demonstrates Consistent Efficacy at 16 Weeks in Patients With Moderate-to-Severe Atopic Dermatitis Regardless of Baseline Disease Severity” (2023) SKIN The Journal of Cutaneous Medicine, 7(6), p. s274. doi:10.25251/skin.7.supp.274.